Cargando…

Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells

BACKGROUND: Drug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance. METHODS: Here, we combined chemotherapy with a newly developed technology, cold...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Dehui, Cui, Qingjie, Xu, Yujing, Chen, Zeyu, Xia, Wenjie, Yang, Yanjie, Liu, Dingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798238/
https://www.ncbi.nlm.nih.gov/pubmed/35117041
http://dx.doi.org/10.21037/tcr.2019.10.43
Descripción
Sumario:BACKGROUND: Drug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance. METHODS: Here, we combined chemotherapy with a newly developed technology, cold atmospheric plasma, to enhance drug sensitivity. RESULTS: We found that plasma treatment had a synergistic anti-cancer effect with a first line drug (bortezomib). Based on our previous study, we further found that plasma treatment could inhibit Notch pathway and down-regulate cyp1a1 expression and enzyme activity, which contributing to the enhanced drug sensitivity to bortezomib after combination of bortezomib with gas plasma. CONCLUSIONS: Our results showed a new strategy to overcome drug resistance by combination of traditional chemotherapy with cold atmospheric plasma.